Cancer treatment gets $0.9 million boost

Israel’s VBL Therapeutics (reported here previously) has been awarded a grant of up to $0.9 million by the Israel Innovation Authority.  It will support the Phase 3 study of VBL’s lead candidate VB-111 for the treatment of platinum-resistant ovarian cancer.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *